Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Id-KLH-pulsed dendritic cells
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
Id-KLH-pulsed dendritic cells are an autologous dendritic cell therapy where dendritic cells are loaded (pulsed) ex vivo with a patient-specific tumor idiotype protein that has been conjugated to the immunogenic carrier protein keyhole limpet hemocyanin (KLH). This approach targets the unique clonal immunoglobulin (idiotype, Id) expressed by B-cell lymphomas, aiming to induce anti-tumor immunity. The therapy is designed to stimulate both cellular (T-cell mediated) and humoral (antibody-mediated) anti-idiotype responses, leading to tumor regression. The therapy has primarily been studied in B-cell non-Hodgkin lymphomas, including follicular lymphoma, and is considered an experimental personalized cancer vaccine and immunotherapy[1].
- Other names
- Id-pulsed dendritic cellsidiotype-pulsed dendritic cellsidiotype-KLH-pulsed dendritic cellsidiotype-keyhole limpet hemocyanin-pulsed dendritic cellsId-KLH-DC vaccine
02
Targets
KLH-peptide-MHC-II (Keyhole limpet hemocyanin-derived peptide-MHC class II complex)Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on Id-KLH-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Id-KLH-pulsed dendritic cells.